Haematology

News

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.

News

China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.

News

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

News

Grifols has filed for FDA approval of its new drug for bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class US launch.